The Food and Drug Administration plays a central role in protecting public health by overseeing food safety, drugs, biologics, medical devices, cosmetics, tobacco and products that emit radiation, according to the agency.
The agency, as reported by FDA materials, comprises multiple centers and offices and maintains a nationwide presence with many field offices and laboratories.
The FDA also relies on a workforce and funding mix to carry out inspections and reviews, with roughly 18,000 employees and an annual budget of about $6.5 billion, the agency reports, and it says roughly 54 percent of that budget comes from federal funding while 46 percent is covered by industry user fees.
The Office of Regulatory Affairs serves as the agency’s primary field operations unit, conducting facility inspections and sampling, and the Office of Criminal Investigations pursues criminal cases, the FDA says, while the agency posts staff internationally to support oversight of imports and global supply chains.
Policy Shifts And Oversight Changes
FDA administrator Marty Makary has set out a series of changes to streamline approvals and alter oversight, as listed by Makary in agency materials and media appearances.
Those items include reducing the number of required pivotal trials for some new drug approvals, adopting Bayesian statistical approaches, and shifting to continuous post approval monitoring, according to the list attributed to Makary.
The list also describes relaxed rules for cellular and gene therapies, less reliance on animal testing in favor of alternatives, and broader availability of some over the counter medicines, as noted by the administrator.
The agency materials attribute additional changes to the food and nutrition agenda, including bans on nine artificial petroleum based food dyes and new public guidance to promote whole foods and revised nutritional priorities.
The FDA has also changed how advisory committees operate, moving them away from routine review of new drug applications and restricting some industry representation where allowed by law, according to agency statements and reporting by industry outlets.
Separately, reporting indicates internal strain. The Guardian reported that the FDA food division head Jim Jones resigned in protest after mass staff cuts, and The New York Times reported the agency signaled narrower approved indications for COVID 19 vaccines while requiring further trials for broader use.
Observers have flagged long standing issues tied to industry funding and committee conflicts of interest, with commentary noting a large share of drug review fees come from pharmaceutical firms, as reported by Forbes, and prior reviews calling for stronger independence and resources for the agency.
The FDA continues to balance complex regulatory duties with evolving policy aims and operational changes, while the agency and external observers weigh potential impacts on safety, access and public confidence.
